- Home
- LTH vs AXSM Comparison
LTH vs AXSM Comparison
Compare LTH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTH
- AXSM
- Stock Information
- Founded
- LTH 1992
- AXSM 2012
- Country
- LTH United States
- AXSM United States
- Employees
- LTH N/A
- AXSM N/A
- Industry
- LTH Hotels/Resorts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- LTH Consumer Discretionary
- AXSM Health Care
- Exchange
- LTH Nasdaq
- AXSM Nasdaq
- Market Cap
- LTH 4.1B
- AXSM 4.4B
- IPO Year
- LTH 2021
- AXSM 2015
- Fundamental
- Price
- LTH $24.98
- AXSM $95.84
- Analyst Decision
- LTH Buy
- AXSM Strong Buy
- Analyst Count
- LTH 10
- AXSM 14
- Target Price
- LTH $24.55
- AXSM $124.57
- AVG Volume (30 Days)
- LTH 1.6M
- AXSM 405.5K
- Earning Date
- LTH 10-23-2024
- AXSM 11-04-2024
- Dividend Yield
- LTH N/A
- AXSM N/A
- EPS Growth
- LTH 26.45
- AXSM N/A
- EPS
- LTH 0.53
- AXSM N/A
- Revenue
- LTH $2,408,489,000.00
- AXSM $291,489,000.00
- Revenue This Year
- LTH $17.12
- AXSM $42.50
- Revenue Next Year
- LTH $9.90
- AXSM $69.28
- P/E Ratio
- LTH $47.09
- AXSM N/A
- Revenue Growth
- LTH 17.97
- AXSM 59.73
- 52 Week Low
- LTH $11.10
- AXSM $55.02
- 52 Week High
- LTH $25.67
- AXSM $98.40
- Technical
- Relative Strength Index (RSI)
- LTH 62.99
- AXSM 64.19
- Support Level
- LTH $24.21
- AXSM $89.24
- Resistance Level
- LTH $25.24
- AXSM $96.71
- Average True Range (ATR)
- LTH 0.69
- AXSM 3.66
- MACD
- LTH 0.01
- AXSM 0.02
- Stochastic Oscillator
- LTH 72.06
- AXSM 87.05
About LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle brand offering health, fitness and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.